Galectin Therapeutics (GALT)
(Delayed Data from NSDQ)
$3.45 USD
-0.05 (-1.43%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.47 +0.02 (0.58%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth A Momentum B VGM
Brokerage Reports
0 items in cart
Galectin Therapeutics Inc. [GALT]
Reports for Purchase
Showing records 1 - 20 ( 105 total )
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
3Q Recap: NAVIGATE Progresses Towards Interim Analysis in 4Q24; We See No Near-Term Financial Overhang; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
2Q Recap; NAVIGATE Interim Analysis On Target For 4Q24; Seeking Options to Advance Belapectin in Oncology; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
1Q Recap; NAVIGATE Phase 2b Interim Analysis in 4Q24 Represents Watershed Moment For Belapectin; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
4Q Recap; NAVIGATE Phase 2b Interim Analysis On Target in 4Q24; Exploring Belapectin Oncology Opportunities; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
NAVIGATE Fully Enrolled; Top-Line Results of Phase 2b Interim Analysis in 4Q24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
NAVIGATE Phase 2b Full Enrollment On Target Around Year- End; Continue to Expect Mid-2024 Interim Readout; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
3Q Recap; Phase 2b NAVIGATE Complete Enrollment Around Year-End; Interim Readout On Target for Mid-2024; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
NAVIGATE Continues As Planned After Second Positive DSMB Review; Complete Enrollment Around Year-End; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
2Q Recap; We Continue to Expect NAVIGATE Phase 2b Data in Mid-2024; Cash Runway Through YE2024; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
New Line of Credit Extends Cash Runway Beyond NAVIGATE''s Phase 2b Interim Readout, Through 2024; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
1Q Recap; NAVIGATE Expands to Mexico and Latin America Sites; Interim Analysis Now in Mid-2024; Moderating PT to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Belapectin Appears Safe and Well-Tolerated in First Positive DSMB Review of NAVIGATE
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
4Q Recap: NAVIGATE Complete Enrollment on Target By End of 2Q22; Preparing Oncology Program IND; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
3Q21 Recap; Details of Company-Sponsored Oncology Program Forthcoming in December Annual Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
New Convertible Debt Financing to Reach Key Value Inflection Point, As Long as NAVIGATE Enrollment Stays on Track
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
2Q21 Recap: 2H23 Interim Readout of NAVIGATE On Target, While Potential in Oncology Emerges; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
1Q21 Recap; NAVIGATE Continues Enrolling Cirrhotic NASH Patients; Key Interim Readout in 2H23; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Published Data Show Belapectin Enhances Cancer Immunotherapy Response
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Galectin Running Full Steam Ahead With Belapectin in Three Clinical Trials; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E